Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign
Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign
复制标题
DOI：
10.1515/cclm-2021-0364
复制
发表时间：
2021-12-01
影响因子：
6.8
通讯作者：
De Vecchi, Elena
中科院分区：
文献类型：
--
作者：
Ferrari, Davide;Mangia, Alessandra;De Vecchi, Elena
目的：经过特殊的研究努力，开发了几种针对SARS-CoV-2的疫苗，该疫苗维持了COVID-19的大流行。Comirnaty疫苗在临床试验中显示出很高的疗效，是第一个被批准向普通人群分发的疫苗。我们评估了在不同性别/年龄组和有或没有天然存在的抗SARS-CoV-2抗体的受试者中第一剂疫苗诱导的免疫应答。研究方法：作为意大利多中心项目（Covidiagnostix）的一部分，使用两种不同的仪器（Siemens-Healthineers和Roche）在首次接种疫苗当天和21天后对4，290名卫生专业人员的血清样本进行了血清学检测。结果如下：总的来说，97%的样本在接种疫苗后21天显示存在特异性抗体;无应答者的百分比随着年龄的增长而增加。值得注意的是，与从未感染过SARS-CoV-2的受试者相比，自然血清阳性个体显示出长达11个月的抗体持续性和异常高的疫苗接种反应。结论：这项研究强调了血清学试验的重要性，i）识别自然SARS-CoV-2血清阳性个体，ii）评估第一剂疫苗接种引起的抗体水平。当受试者按性别和年龄分层时，以及自然血清反应阳性和血清反应阴性受试者之间，这两种测试都突出了免疫应答的差异。所获得的数据显示，血清学检测如何在接受COVID-19疫苗接种活动的人群的分诊中发挥关键作用。需要定义合适的仪器特异性阈值，以正确跟踪一般人群中最终获得的疫苗接种后免疫力。
Objectives: After exceptional research efforts, several vaccines were developed against SARS-CoV-2 which sustains the pandemic COVID-19. The Comirnaty vaccine showed high efficacy in clinical trials and was the first to be approved for its distribution to the general population. We evaluated the immune response induced by the first vaccine dose in different sex/age groups and subjects with or without naturally present anti-SARS-CoV-2 antibodies. Methods: As part of an Italian multicenter project (Covidiagnostix), serum samples from 4,290 health professionals were serologically tested the day of the first vaccination dose, and 21 days later, using two different instrumentations (Siemens-Healthineers and Roche). Results: In total, 97% of samples showed the presence of specific antibodies 21 days after the vaccination dose; the percentage of non-responders increased with age in both genders. Remarkably, naturally seropositive individuals showed antibody persistence up to 11 months and an exceptionally higher vaccination response compared to subjects never infected by SARS-CoV-2. Conclusions: This study highlighted the importance of the serological test i) to identify naturally SARS-CoV-2 seropositive individuals and ii) to evaluate the antibody level elicited by the first vaccination dose. Both tests, highlighted differences in the immune response, when subjects were stratified by sex and age, and between naturally seropositive and seronegative subjects. The data obtained show how serological tests could play a crucial role in the triage of the population subjected to the vaccination campaign for COVID-19. The definition of suitable instrumentation-specific thresholds is needed to correctly follow eventually acquired post-vaccination immunity in the general population.